ADRB3

ADRB3

A gene on chromosome 8p12 that encodes beta-1-adrenergic receptor, a member of the G protein-coupled receptor superfamily, which mediates catecholamine-induced activation of adenylate cyclase. ADRB3 is located primarily in adipose tissue and is involved in regulating lipolysis and thermogenesis.
References in periodicals archive ?
Association studies on the porcine RETN, UCP1, UCP3 and ADRB3 genes polymorphism with fatness traits.
Finelli et al., "The absence of polymorphisms in ADRB3, UCP1, PPAR[gamma], and ADIPOQ genes protects morbid obese patients toward insulin resistance," Journal of Endocrinology Investigation, vol.
The PPI established between the ZIKV M protein and the ADRB3, a beta-3 adrenergic receptor, also has a 0.4 score.
The [AC.sub.50] values for amitraz for [alpha]-2A and [alpha]-2b adrenergic receptors were 0.05-1.6 [micro]M (ADRA2A, Adra2a, Adra2b), but this was not the case for other adrenergic receptor subtypes [[alpha]-2C (ADRA2C), [beta]-1 (ADRBI), [beta]-2 (ADRB2), P-3 (ADRB3)].
El tercer estudio, llevado a cabo en probandos de la Ciudad de Mexico, con variantes en 14 genes candidato para sindrome metabolico, mostro que las variantes en TCF7L2 estaban fuertemente correlacionadas con la DM2 y otro nuevo marcador asociado; el SNP rs4994 del gen ADRB3 (38).
Interaction of single nucleotide polymorphisms in ADRB2, ADRB3, TNF, IL6, IGF1R, LIPC, LEPR, and GHRL with physical activity on the risk of type 2 diabetes mellitus and changes in characteristics of the metabolic syndrome: The Finnish Diabetes Prevention Study.
When TRIP-Br2 is suppressed, the expression of hormone sensitive lipase (HSL) and Beta3-adrenergic (Adrb3) receptors, which are involved in fat breakdown (lipolysis), is significantly enhanced in fat tissue.
Category Group Regulated core genes Cardiac hypertrophy WB TPM1.FGF23 Cardiac hypertrophy Imipramine EPO, UCN2, TERT, VDR, ACE Cardiac arrhythmia lmipramine ATP1A3, SCN1A, KCNH7, KCNG2, KCNQ1, ADORA1, ADRA1B, ADRB3, ADRA1D Cardiac adenopathy EtOH-Fr DLCAP4, MTHFS, EVC2, MAPK9.
Of them, 25 were associated with an increased risk for T2D and they were located in 20 genes, namely, ABCA1, ADRB3, CAPN10, CDC123/CAMK1D, CDKN2A/2B, CRP, ELMO1, FTO, HHEX, IGF2BP2, IRS1, JAZF1, KCNQ1, LOC387761, LTA, NXPH1, SIRT1, SLC30A8, TCF7L2, and TNF-[alpha].
The two genotypes (CCArgArg and CCTrpArg) of [[beta].sub.2]-adrenergic receptor gene (ADRB2) and [[beta].sub.3]-adrenergic receptor gene (ADRB3) were separated into the risk and protective genotype groups (p<0.05) in spite of their corresponding initial phenotypic means (p>0.05).
Term Count P value Genes MAPK signaling pathway 13 0.0062 RPS6KA5, AKT1, MAP4K4, MAP3K5, PLA2G4A, DUSP2, FGF9, TGFBR1, MAP2K4, MKNK2, PPP3R1, FGF12, DUSP6 Endocytosis 10 0.010 IGF1R, ADRB3, FLT1, TGFBR1, PSD3, VPS4B, DNAJC6, PSD2, ARAP2, LDLRAP1 Axon guidance 7 0.042 EPHA5, SEMA6A, PLXNA1, PPP3R1, SEMA4C, L1CAM, SRGAP1 Insulin signaling 6 0.0076 AKT1, L1CAM, IGF1R, IRS2, pathway SOCS7, RHOQ Focal adhesion 4 0.021 VCAM1, L1CAM, ITGA4, CERCAM Table 2: Small molecules which might reverse the dysregulation of AD in EC and HIP regions.